NasdaqGS - Nasdaq Real Time Price USD

Gilead Sciences, Inc. (GILD)

Compare
83.94 +0.04 (+0.05%)
At close: September 20 at 4:00 PM EDT
83.70 -0.24 (-0.29%)
After hours: September 20 at 7:39 PM EDT
Loading Chart for GILD
DELL
  • Previous Close 83.90
  • Open 83.26
  • Bid 78.85 x 100
  • Ask 87.45 x 100
  • Day's Range 82.75 - 83.99
  • 52 Week Range 62.07 - 87.87
  • Volume 24,672,671
  • Avg. Volume 6,673,338
  • Market Cap (intraday) 104.504B
  • Beta (5Y Monthly) 0.20
  • PE Ratio (TTM) 102.37
  • EPS (TTM) 0.82
  • Earnings Date Nov 7, 2024
  • Forward Dividend & Yield 3.08 (3.67%)
  • Ex-Dividend Date Sep 13, 2024
  • 1y Target Est 82.33

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

www.gilead.com

18,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GILD

View More

Performance Overview: GILD

Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

GILD
6.95%
S&P 500
19.55%

1-Year Return

GILD
15.39%
S&P 500
28.32%

3-Year Return

GILD
32.73%
S&P 500
28.64%

5-Year Return

GILD
56.24%
S&P 500
89.66%

Compare To: GILD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GILD

View More

Valuation Measures

Annual
As of 9/20/2024
  • Market Cap

    104.50B

  • Enterprise Value

    125.08B

  • Trailing P/E

    102.37

  • Forward P/E

    11.71

  • PEG Ratio (5yr expected)

    0.50

  • Price/Sales (ttm)

    3.78

  • Price/Book (mrq)

    5.72

  • Enterprise Value/Revenue

    4.50

  • Enterprise Value/EBITDA

    23.73

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.79%

  • Return on Assets (ttm)

    11.55%

  • Return on Equity (ttm)

    5.26%

  • Revenue (ttm)

    27.8B

  • Net Income Avi to Common (ttm)

    1.05B

  • Diluted EPS (ttm)

    0.82

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.78B

  • Total Debt/Equity (mrq)

    128.32%

  • Levered Free Cash Flow (ttm)

    6.79B

Research Analysis: GILD

View More

Company Insights: GILD

Research Reports: GILD

View More

People Also Watch